Seeing as RXMD REVS are currently $40.6M for 2020, and GoodRx IPO'D at 7X trailing sales - that puts RXMD at a minimum ballpark $280M COMPARABLE VALUE TO GOODRX at $2.8B
PRE-M&A RXMD IS WORTH 280M/502M= .5577/SHARE TODAY POST-M&A adding +60M REVS = 100M REVS X 7X trailing sales =$700M COMPARABLE VALUE - SAY M&A DILUTES COMPLETELY TO $1B OS - THAT WOULD GIVE RXMD A COMPARABLE VALUE OF $.70/SHARE 700M/1B = .70/share
That article gives GoodRx a chance to be a 10 bagger from these levels - when applied to RXMD that gets the numbers up to as high as $5/share.
All this and we are trading at just .13/share today which is only 1.5X 2020 sales
There is SUCH A WIDE DISPARITY BETWEEN CURRENT PRICE AND A MINIMALLY TRUE VALUATION
TRUE PRICE is where a stock price *settles, not its HIGH... A .5577 TRUE PRICED STOCK could easily run to $1-$1.50 before settling at .5577. Same for .70, after the addition of $65M more REVS we could touch even higher before settling down
TOO MANY TRADERS ARE SETTLING FOR .13 WHEN A CLEAR PATH TO 8X-10X THAT IS RIGHT IN FRONT OF US - AND LIKE THISMONTH IN FRONT OF US.....
I GUESS THATS WHY 5% OF PEOPLE MAKE 90% OF THE $ IN THIS WORLD - EITHER YOU SEE IT OR YOU DONT
- BE ONE OF THOSE THAT PATIENCE REWARDS WITH LIFE CHANGING RETURNS IN 2021 - WE WONT HIT A MATURE NUMBER LIKE $5 THIS YEAR, BUT $1+ IS ABSOLUTELY NOT OUT OF THE QUESTION!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.